TP53 and cancer: Given that USP28-mediated activation of p53 is critical for mounting an effective response to mitotic stress response and in some cancers to DNA damage response, disruption of its interaction with 53BP1 could contribute to therapeutic resistance, particularly against anti-mitotic and DNA-damaging agents.